Get the Stockscreener App
35.89
0.64%
0.23
After Hours:
35.85
-0.04
-0.11%
Moderna Inc stock is traded at $35.89, with a volume of 13.83M.
It is up +0.64% in the last 24 hours and up +29.57% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$35.66
Open:
$34.5
24h Volume:
13.83M
Relative Volume:
1.31
Market Cap:
$14.02B
Revenue:
$3.14B
Net Income/Loss:
$-3.36B
P/E Ratio:
-4.1111
EPS:
-8.73
Net Cash Flow:
$-4.03B
1W Performance:
+21.70%
1M Performance:
+29.57%
6M Performance:
+20.03%
1Y Performance:
-24.49%
1-Day Range:
$34.42
$37.10
1-Week Range:
$29.81
$37.10
52-Week Range:
$22.28
$47.70
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
35.89 | 13.93B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-25 | Initiated | Jefferies | Hold |
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
What Analysts Are Saying About Moderna Stock - Benzinga
UBS Lowers Moderna (MRNA) Price Target to $34, Rating Changed to Neutral | MRNA Stock News - GuruFocus
Here Are Wednesday’s Top Wall Street Analyst Research Calls: Applied Digital, BigBear.ai, Block, Deckers Outdoors, GitLab, Hershey, McDonald's, Moderna, and More - 24/7 Wall St.
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX) and Moderna (MRNA) - The Globe and Mail
Bayer sues COVID vaccine makers over mRNA technology - ETPharma.com
My Top 5 Stocks to Buy in Early 2026 - The Motley Fool
Moderna (MRNA) Soars 10.9%: Is Further Upside Left in the Stock? - Nasdaq
Moderna Announces Updated COVID-19 Vaccine Against LP.8.1 Variant Generates Strong Immune Response in Humans - The Asheville Citizen Times
Bayer Sues Biontech and Pfizer Over Patents for Covid Vaccines - MarketScreener
Bayer Targets Pfizer, Moderna, J&J For Covid Jab Royalties - Law360
Moderna, Inc. (MRNA) Issues Shareholder Letter Highlighting Strategic Developments - GuruFocus
Bayer Seeks Covid-Vaccine Royalties Over Crop-Technology Patent - Bloomberg Law News
UBS Downgrades Moderna (MRNA) Amid Revenue Concerns - GuruFocus
Moderna downgraded to neutral at UBS on questions over revenue growth - MSN
Moderna (NASDAQ:MRNA) Stock Price Up 8.6%Time to Buy? - MarketBeat
Moderna stock jumps nearly 11% after BofA target lift; flu vaccine filing in focus - TechStock²
MRNA Stock Jumps on Global Submissions Seeking Nod for Flu Vaccine - The Globe and Mail
Moderna jumps 10% as BofA hikes target price - breakingthenews.net
Moderna rallies after BofA raises its price target to $24 from $21 - Sherwood News
BofA Adjusts Price Target on Moderna to $24 From $21, Maintains Underperform Rating - MarketScreener
CEPI to Fund Pivotal Phase 3 Trial for Moderna's mRNA Pandemic Influenza Vaccine Candidate - Record-Courier
Moderna stock price target raised to $24 from $21 at BofA Securities - Investing.com UK
Moderna Announces Global Regulatory Submissions for Its Investigational Seasonal Influenza Vaccine - Bartlesville Examiner-Enterprise
Moderna reaffirms 2025-26 guidance, eyes multiple vaccine, oncology, and rare disease launches - Proactive financial news
Key facts: Moderna announces 2025 achievements; mRNA-1010 shows efficacy - TradingView — Track All Markets
CDC updates childhood vaccine schedule (PFE:NYSE) - Seeking Alpha
Jefferies reiterates Hold rating on Moderna stock, maintains $30 price target - Investing.com UK
Moderna, searching for a rebound, to seek approval of mRNA flu shot - BioPharma Dive
Moderna says aiming at 2025 projected revenue range of $1.6 bln to $2.0 bln - MarketScreener
Moderna (MRNA) Gains Ground Amid Flu Vaccine Regulatory Submissions - thebull.com.au
Moderna issues shareholder letter under Regulation FD disclosure - Investing.com
Moderna Highlights 2025 Progress and Strengthened Vaccine Portfolio - TipRanks
Moderna issues shareholder letter under Regulation FD disclosure By Investing.com - Investing.com South Africa
Moderna, Inc. Reports 2025 Achievements and 2026 Outlook - TradingView — Track All Markets
Moderna (MRNA) Advances Seasonal Flu Vaccine Regulatory Submissi - GuruFocus
Moderna (MRNA) Seeks Approval for New Influenza Vaccine - GuruFocus
Moderna (MRNA) Seeks Approval for New Flu Vaccine Targeting Olde - GuruFocus
Moderna seeks global approvals for flu shot - MSN
Moderna seeks global approvals for flu shot (MRNA:NASDAQ) - Seeking Alpha
Moderna files for approval of flu vaccine in four countries - StreetInsider
New mRNA flu shot from Moderna may better match evolving virus strains - Stock Titan
Moderna, Inc. (MRNA) Stock Analysis: Navigating a 19% Upside Potential Amidst Revenue Challenges - DirectorsTalk Interviews
Moderna to Present at the 44th Annual J.P. Morgan Healthcare Conference - Alliance Review
Moderna (MRNA): Reassessing Valuation After a Modest Share Price Rebound - Yahoo Finance
Moderna Announces First Patient Dosed in Phase 1/2 Study of Investigational T-Cell Engager for Multiple Myeloma - Victorville Daily Press
Moderna Vaccine (Spikevax): Why This COVID Shot Is Still at the Center of the Conversation - AD HOC NEWS
Moderna is rising today: what traders are watching (January 2) - Traders Union
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
28.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):